Primo Biotechnology Partners with SHINE Technologies to Distribute Ilumira® in Asia-Pacific

Primo Biotechnology (“Primo”) announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear ...

January 09, 2025 | Thursday | News
Merck's GARDASIL® Becomes First HPV Vaccine Approved for Males in China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the National Medical Products Administration (NMPA) of China approv...

January 09, 2025 | Thursday | News
Jacobio Pharma's KRAS G12C Inhibitor Glecirasib Data Published in Nature Medicine, Showcasing Impressive Efficacy in NSCLC

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced that the data from a registrational clinical trial of...

January 07, 2025 | Tuesday | News
Astellas’ VYLOY™ (Zolbetuximab) Approved in China for First-Line Treatment of Advanced Gastric and GEJ Cancer

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that China's National Medical Products Administ...

January 06, 2025 | Monday | News
GSK's Nucala (Mepolizumab) Approved in China for Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

GSK plc (LSE/NYSE: GSK) announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibod...

January 06, 2025 | Monday | News
Panic Grips China as Human Metapneumovirus Outbreak Sparks Global Concerns

  A wave of panic is sweeping across China as distressing reports and videos of overwhelmed hospitals surface online. This time, the spotlight is on ...

January 03, 2025 | Friday | News
Innovent Biologics Receives NMPA Approval for DOVBLERON® (Taletrectinib Adipate) as a Treatment for ROS1-Positive NSCLC

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

January 03, 2025 | Friday | News
HUTCHMED and AstraZeneca's ORPATHYS® + TAGRISSO® Combo for MET-Driven NSCLC Granted Priority Review by China’s NMPA

HUTCHMED (China) announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO&re...

January 02, 2025 | Thursday | News
Genesis Medtech Launches iReach Omnia, World’s First Powered Stapler with 90° Articulation, in China

Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90° articulation capability, has been approved for marke...

January 02, 2025 | Thursday | News
CARsgen Therapeutics Launches Investigator-Initiated Trial in China for KJ-C2219, an Allogeneic CAR T-Cell Therapy Targeting CD19/CD20

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

January 01, 2025 | Wednesday | News
IDEAYA Biosciences Acquires Global Rights to SHR-4849 DLL3-Targeting ADC in $1 Billion Agreement with Hengrui Pharma

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, an...

December 30, 2024 | Monday | News
Keymed Biosciences Secures NMPA Approval for Stapokibart in Treating Chronic Rhinosinusitis with Nasal Polyposis

Keymed Biosciences Inc. announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Appl...

December 27, 2024 | Friday | News
HKBU and Shanghai Sixth People's Hospital Pioneer Breakthrough Treatment for Rare Bone Disease XLH

A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People's Hospital Affiliated to School of Medicine at Shanghai Jiao ...

December 23, 2024 | Monday | News
CStone Pharmaceuticals Submits Clinical Trial Application for CS2009, a Tri-Specific Antibody Targeting PD-1, VEGF, and CTLA-4 for Solid Tumors

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

December 23, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close